Danish drug developer Novo Nordisk said it would have to halve the supply of starter doses of its popular Wegovy weight-loss drug in the United States to cope with high demand after reporting forecast-beating results on Thursday.
Firm reports forecast-beating Q1 resultsCOPENHAGEN, May 4 - Danish drug developer Novo Nordisk
Shares in Novo Nordisk traded down 4.7% at 0731 GMT, putting a small dent in a rise of more than 140% since the firm launched Wegovy in the U.S. in June 2021. The company's stock is the best performing in Europe. Novo has faced supply constraints for its hugely popular Wegovy drug as a result of overwhelming demand, and has invested massively in increasing supply."We cannot supply an uptake that just continues growing, so it's important for us that we secure continuity of supply for those patients who have started treatment," Chief Executive Lars Fruergaard Jorgensen told journalists on Thursday.
"We will gradually roll out in International Operations, and UK is a part of that. We are not commenting on specific launch dates," he said.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
An unfriendly battle over pride banners in friendly-branded SolvangThe feud in the Danish-themed tourist town led an actual Danish leader to step in.
Consulte Mais informação »
Investors see big Novo Nordisk stock boost if obesity drug shows heart benefitPositive trial data showing Novo Nordisk’s obesity drug helps save and extend lives, not just lose weight, could propel Europe's best-performing stock even higher, according to 10 investors and industry analysts interviewed by Reuters.
Consulte Mais informação »
Wegovy Maker to Limit Starter-Dose Supplies in U.S. as Demand SurgesLower-strength starter doses of the obesity drug will be held back in the U.S. to safeguard supplies, said pharmaceutical company Novo Nordisk.
Consulte Mais informação »
Safety worries over copycat versions of Ozempic and Wegovy prompt state crackdownsA growing number of states are threatening to take legal action against pharmacies that make or dispense unauthorized versions of Ozempic and Wegovy.
Consulte Mais informação »
Ozempic, Wegovy and all those crazy, vivid dreams: Is there a connection?Many people taking Ozempic for weight loss or Wegovy for diabetes management have reported vivid, intense dreams and nightmares as a side effect of the semaglutide medications.
Consulte Mais informação »
Pandora Sales Rise 1 Percent in Q1, Raises GuidanceThe Danish jewelry giant tightened its guidance for 2023.
Consulte Mais informação »